All patients
cell type, non squamous cell cell type, squamous cell PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L2 - all population, nivolumab alone vs. taxanes, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 078, 2019 0.68 [0.52; 0.89]
0.68 [0.52 ; 0.89 ] CheckMate 078, 2019 1 0% 504 NA not evaluable deaths (OS) (extension)detailed results CheckMate 078, 2019 0.75 [0.61; 0.93]
0.75 [0.61 ; 0.93 ] CheckMate 078, 2019 1 0% 504 NA not evaluable PFS (extension)detailed results CheckMate 078, 2019 0.79 [0.64; 0.97]
0.79 [0.64 ; 0.97 ] CheckMate 078, 2019 1 0% 504 NA not evaluable progression or deaths (PFS)detailed results CheckMate 078, 2019 0.77 [0.62; 0.95]
0.77 [0.62 ; 0.95 ] CheckMate 078, 2019 1 0% 504 NA not evaluable objective responses (ORR)detailed results CheckMate 078, 2019 4.40 [1.99; 9.74]
4.40 [1.99 ; 9.74 ] CheckMate 078, 2019 1 0% 504 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 078, 2019 4.80 [2.14; 10.77]
4.80 [2.14 ; 10.77 ] CheckMate 078, 2019 1 0% 504 NA not evaluable STRAE (any grade)detailed results CheckMate 078, 2019 0.59 [0.34; 1.02]
0.59 [0.34 ; 1.02 ] CheckMate 078, 2019 1 0% 493 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 078, 2019 0.34 [0.18; 0.66]
0.34 [0.18 ; 0.66 ] CheckMate 078, 2019 1 0% 493 NA not evaluable TRAE (any grade)detailed results CheckMate 078, 2019 0.35 [0.22; 0.57]
0.35 [0.22 ; 0.57 ] CheckMate 078, 2019 1 0% 493 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.15 [0.10; 0.24]
0.15 [0.10 ; 0.24 ] CheckMate 078, 2019 1 0% 493 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 078, 2019 0.61 [0.14; 2.77]
0.61 [0.14 ; 2.77 ] CheckMate 078, 2019 1 0% 493 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 078, 2019 0.66 [0.32; 1.37]
0.66 [0.32 ; 1.37 ] CheckMate 078, 2019 1 0% 493 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 078, 2019 0.80 [0.33; 1.95]
0.80 [0.33 ; 1.95 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.15 [0.02; 1.47]
0.15 [0.02 ; 1.47 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
0.93 [0.03 ; 27.74 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.27 [0.06; 1.15]
0.27 [0.06 ; 1.15 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
0.93 [0.03 ; 27.74 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.23 [0.01; 6.90]
0.23 [0.01 ; 6.90 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.03; 7.42]
0.46 [0.03 ; 7.42 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.03; 7.42]
0.46 [0.03 ; 7.42 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.02 [0.00; 0.18]
0.02 [0.00 ; 0.18 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.03 [0.01; 0.15]
0.03 [0.01 ; 0.15 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 078, 2019 3.74 [0.20; 71.10]
3.74 [0.20 ; 71.10 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 6.60 [0.37; 116.99]
6.60 [0.37 ; 116.99 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 02:03 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 37
- treatments: 360,719,721,720